Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Terry Chrisomalis
Investing Group Leader
(15min)

Summary

  • Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025.
  • It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035.
  • VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
  • PCVX is attempting to expand its program in the prevention of IPD with candidates VAX-31 and VAX-XL; The goal is broaden the disease that can be targeted.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Indian Lab Technician Analyzes Samples

sanjeri/E+ via Getty Images

The last time I spoke about Vaxcyte, Inc. (NASDAQ:PCVX) it was in a Seeking Alpha article entitled "Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.39K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About PCVX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on PCVX

Related Stocks

SymbolLast Price% Chg
PCVX
--
Compare

Trending Analysis

Trending News